Skip to main content
NCBI home page
Elsevier Sponsored Documents logoLink to Elsevier Sponsored Documents
. 2020 Sep 17;182(6):1663–1673. doi: 10.1016/j.cell.2020.08.046

Longitudinal Isolation of Potent Near-Germline SARS-CoV-2-Neutralizing Antibodies from COVID-19 Patients

Christoph Kreer, Matthias Zehner, Timm Weber, Meryem S Ercanoglu, Lutz Gieselmann, Cornelius Rohde, Sandro Halwe, Michael Korenkov, Philipp Schommers, Kanika Vanshylla, Veronica Di Cristanziano, Hanna Janicki, Reinhild Brinker, Artem Ashurov, Verena Krähling, Alexandra Kupke, Hadas Cohen-Dvashi, Manuel Koch, Jan Mathis Eckert, Simone Lederer, Nico Pfeifer, Timo Wolf, Maria JGT Vehreschild, Clemens Wendtner, Ron Diskin, Henning Gruell, Stephan Becker, Florian Klein ∗
PMCID: PMC7497397  PMID: 32946786

(Cell 182, 843–854.e1–e12; August 20, 2020)

We discovered that values for 2 out of 79 antibodies have unfortunately been wrongly reported. For antibody FnC1t1p2_A5, the IC100 is 50 μg/mL instead of 16 μg/mL; for antibody CnC2t1p1_B10, the IC100 is >100 μg/mL instead of 12.5 μg/mL. For the latter antibody, binding characteristics were also corrected. As a consequence, the total number of neutralizing antibodies reported is 27 instead of 28. Changes affect Figures 3, 4, S3, S4, and S5, Tables S3 and S4, and text on pages 1, 3, 5, and 7. Importantly, the corrections have no impact on the conclusions in this paper. We apologize for any inconvenience that may have been caused by this error.

Figure 3.

Figure 3

Open in a new tab

Infected individuals can develop potent near-germline SARS-CoV-2-neutralizing antibodies that preferentially bind to the S-protein RBD (corrected)

Figure 3.

Figure 3

Open in a new tab

Infected individuals can develop potent near-germline SARS-CoV-2-neutralizing antibodies that preferentially bind to the S-protein RBD (original)

Figure 4.

Figure 4

Open in a new tab

Dynamics of somatic mutations for SARS-CoV-2-specific antibodies (corrected)

Figure 4.

Figure 4

Open in a new tab

Dynamics of somatic mutations for SARS-CoV-2-specific antibodies (original)

Figure S3.

Figure S3

Open in a new tab

Correlation of binding and neutralization with VH gene characteristics (corrected)

Figure S3.

Figure S3

Open in a new tab

Correlation of binding and neutralization with VH gene characteristics (original)

Figure S4.

Figure S4

Open in a new tab

VL gene distribution in non-neutralizing and neutralizing antibodies (corrected)

Figure S4.

Figure S4

Open in a new tab

VL gene distribution in non-neutralizing and neutralizing antibodies (original)

Figure S5.

Figure S5

Open in a new tab

Autoreactivity of selected SARS-CoV-2-binding and -neutralizing antibodies (corrected)

Figure S5.

Figure S5

Open in a new tab

Autoreactivity of selected SARS-CoV-2-binding and -neutralizing antibodies (original)

RESOURCES